SUN24595, also known as NF-κB activator 1, is a potent NF-κB activator with EC50 of 0.9 μM. SUN24595 induces superoxide dismutase (SOD)2 mRNA expression. SUN24595 was first reported in European Journal of Medicinal Chemistry (2021), 210, 112952. The product currently has no official name.

Physicochemical Properties

Molecular Formula	C16H11FN2O2S
Molecular Weight	314.334145784378
Exact Mass	314.05
Elemental Analysis	C, 61.14; H, 3.53; F, 6.04; N, 8.91; O, 10.18; S, 10.20
CAS #	2387524-59-4
PubChem CID	151901137
Appearance	Light yellow to yellow solid powder
LogP	4.1
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	4
Heavy Atom Count	22
Complexity	398
Defined Atom Stereocenter Count	0
SMILES	S1C=C(C2C=CC=C(C(=O)O)C=2)N=C1NC1C=CC=CC=1F
InChi Key	SSUFECODNVILSX-UHFFFAOYSA-N
InChi Code	InChI=1S/C16H11FN2O2S/c17-12-6-1-2-7-13(12)18-16-19-14(9-22-16)10-4-3-5-11(8-10)15(20)21/h1-9H,(H,18,19)(H,20,21)
Chemical Name	3-(2-((2-fluorophenyl)amino)thiazol-4-yl)benzoic acid
Synonyms	NF-κΒ activator 1; SUN24595; SUN-24595; SUN 24595;
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

References

[1]. Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS [published online ahead of print, 2020 Oct 22]. Eur J Med Chem. 2020;112952.

Solubility Data

Solubility (In Vitro)

DMSO : ~125 mg/mL (~397.67 mM)

Solubility (In Vivo)

Solubility in Formulation 1: 2.08 mg/mL (6.62 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (6.62 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.1814 mL	15.9068 mL	31.8137 mL
	5 mM	0.6363 mL	3.1814 mL	6.3627 mL
	10 mM	0.3181 mL	1.5907 mL	3.1814 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.